Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 8 | 2022 | 918 | 1.940 |
Why?
|
| Vietnam | 16 | 2026 | 177 | 1.090 |
Why?
|
| Hospitalization | 6 | 2018 | 1385 | 0.940 |
Why?
|
| Hypertension | 6 | 2023 | 609 | 0.860 |
Why?
|
| Patients | 2 | 2021 | 114 | 0.780 |
Why?
|
| Clinical Laboratory Services | 1 | 2021 | 5 | 0.700 |
Why?
|
| Medical Laboratory Personnel | 1 | 2021 | 10 | 0.700 |
Why?
|
| Hospital Mortality | 5 | 2022 | 874 | 0.690 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2022 | 95 | 0.660 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 108 | 0.650 |
Why?
|
| Patient Education as Topic | 3 | 2023 | 481 | 0.600 |
Why?
|
| Water Pollutants, Chemical | 1 | 2019 | 42 | 0.570 |
Why?
|
| Chitosan | 1 | 2019 | 87 | 0.550 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 460 | 0.550 |
Why?
|
| Sample Size | 1 | 2017 | 66 | 0.520 |
Why?
|
| Hospital Administration | 2 | 2014 | 43 | 0.520 |
Why?
|
| Life Style | 1 | 2018 | 320 | 0.500 |
Why?
|
| Aged | 20 | 2024 | 14840 | 0.490 |
Why?
|
| Forecasting | 1 | 2017 | 229 | 0.490 |
Why?
|
| Sex Factors | 4 | 2014 | 989 | 0.480 |
Why?
|
| Health Behavior | 1 | 2018 | 482 | 0.450 |
Why?
|
| Healthcare Disparities | 2 | 2010 | 406 | 0.450 |
Why?
|
| Patient Selection | 1 | 2017 | 483 | 0.440 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 861 | 0.430 |
Why?
|
| Developing Countries | 4 | 2023 | 87 | 0.410 |
Why?
|
| Male | 26 | 2024 | 30812 | 0.400 |
Why?
|
| Age Factors | 4 | 2018 | 1580 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2019 | 768 | 0.390 |
Why?
|
| Female | 27 | 2024 | 33765 | 0.390 |
Why?
|
| Acute Coronary Syndrome | 2 | 2018 | 252 | 0.370 |
Why?
|
| Sex Characteristics | 1 | 2014 | 211 | 0.370 |
Why?
|
| Aedes | 4 | 2016 | 13 | 0.370 |
Why?
|
| Risk Assessment | 2 | 2017 | 2091 | 0.370 |
Why?
|
| Humans | 40 | 2024 | 64778 | 0.360 |
Why?
|
| Dengue | 4 | 2016 | 96 | 0.360 |
Why?
|
| Dengue Virus | 3 | 2015 | 99 | 0.320 |
Why?
|
| Myocardial Revascularization | 1 | 2010 | 78 | 0.310 |
Why?
|
| Nurses | 2 | 2021 | 107 | 0.310 |
Why?
|
| Outpatients | 2 | 2022 | 142 | 0.310 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 106 | 0.300 |
Why?
|
| Noncommunicable Diseases | 2 | 2019 | 18 | 0.300 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 433 | 0.290 |
Why?
|
| Middle Aged | 14 | 2022 | 18112 | 0.290 |
Why?
|
| Transportation of Patients | 1 | 2009 | 50 | 0.290 |
Why?
|
| Heart Block | 1 | 2008 | 21 | 0.280 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5565 | 0.280 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 456 | 0.280 |
Why?
|
| Inpatients | 1 | 2010 | 314 | 0.270 |
Why?
|
| Prognosis | 4 | 2018 | 1773 | 0.250 |
Why?
|
| African Swine Fever | 1 | 2026 | 1 | 0.240 |
Why?
|
| African Swine Fever Virus | 1 | 2026 | 1 | 0.240 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 2483 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 489 | 0.220 |
Why?
|
| Incidence | 5 | 2018 | 1410 | 0.220 |
Why?
|
| Adult | 15 | 2023 | 17243 | 0.220 |
Why?
|
| Pharmacists | 3 | 2020 | 130 | 0.200 |
Why?
|
| Adenoma | 1 | 2023 | 68 | 0.190 |
Why?
|
| Esophagitis | 1 | 2022 | 9 | 0.190 |
Why?
|
| Risk Factors | 6 | 2018 | 5399 | 0.190 |
Why?
|
| Peptic Ulcer | 1 | 2022 | 18 | 0.190 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 292 | 0.190 |
Why?
|
| Pain Measurement | 2 | 2021 | 340 | 0.190 |
Why?
|
| Propofol | 1 | 2022 | 21 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 93 | 0.180 |
Why?
|
| Ketamine | 1 | 2022 | 38 | 0.180 |
Why?
|
| Public Health | 2 | 2021 | 186 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2023 | 140 | 0.170 |
Why?
|
| Drug Hypersensitivity | 1 | 2021 | 27 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5764 | 0.170 |
Why?
|
| Blood Culture | 1 | 2020 | 8 | 0.160 |
Why?
|
| Time Factors | 4 | 2018 | 3753 | 0.160 |
Why?
|
| Dementia | 1 | 2024 | 272 | 0.160 |
Why?
|
| Frailty | 1 | 2022 | 128 | 0.150 |
Why?
|
| Pharmacy Technicians | 1 | 2019 | 1 | 0.150 |
Why?
|
| Bacteremia | 1 | 2020 | 92 | 0.150 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2751 | 0.150 |
Why?
|
| Videotape Recording | 1 | 2019 | 46 | 0.150 |
Why?
|
| Computers, Handheld | 1 | 2019 | 37 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 181 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 385 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 104 | 0.150 |
Why?
|
| Pandemics | 2 | 2023 | 669 | 0.150 |
Why?
|
| Charcoal | 1 | 2019 | 6 | 0.150 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 869 | 0.150 |
Why?
|
| Magnetic Phenomena | 1 | 2019 | 7 | 0.150 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 33 | 0.150 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 29 | 0.150 |
Why?
|
| Coffee | 1 | 2019 | 18 | 0.150 |
Why?
|
| Ions | 1 | 2019 | 54 | 0.150 |
Why?
|
| Tea | 1 | 2019 | 32 | 0.150 |
Why?
|
| Adsorption | 1 | 2019 | 87 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2021 | 365 | 0.150 |
Why?
|
| Massachusetts | 3 | 2017 | 2137 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2023 | 3299 | 0.140 |
Why?
|
| Insect Vectors | 2 | 2015 | 15 | 0.140 |
Why?
|
| Warfarin | 1 | 2019 | 124 | 0.140 |
Why?
|
| Prevalence | 3 | 2022 | 1434 | 0.140 |
Why?
|
| Growth | 1 | 2018 | 23 | 0.140 |
Why?
|
| Short Bowel Syndrome | 1 | 2018 | 6 | 0.140 |
Why?
|
| Talaromyces | 1 | 2017 | 1 | 0.140 |
Why?
|
| Itraconazole | 1 | 2017 | 14 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2018 | 30 | 0.140 |
Why?
|
| Minority Groups | 1 | 2019 | 141 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2019 | 198 | 0.140 |
Why?
|
| Dermatomycoses | 1 | 2017 | 18 | 0.140 |
Why?
|
| Multiple Chronic Conditions | 1 | 2018 | 39 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 465 | 0.130 |
Why?
|
| Plant Extracts | 1 | 2019 | 129 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 798 | 0.130 |
Why?
|
| Poverty | 1 | 2019 | 299 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 207 | 0.130 |
Why?
|
| Kinetics | 1 | 2019 | 758 | 0.130 |
Why?
|
| Rural Population | 1 | 2019 | 221 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2017 | 142 | 0.130 |
Why?
|
| Child Development | 1 | 2018 | 87 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2017 | 130 | 0.130 |
Why?
|
| Mosquito Control | 1 | 2016 | 8 | 0.120 |
Why?
|
| Quality of Life | 1 | 2024 | 1254 | 0.120 |
Why?
|
| Insect Repellents | 1 | 2016 | 3 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 222 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 270 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 433 | 0.120 |
Why?
|
| Culture | 2 | 2016 | 80 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2019 | 1002 | 0.110 |
Why?
|
| Wolbachia | 1 | 2015 | 5 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2016 | 134 | 0.110 |
Why?
|
| Income | 3 | 2021 | 170 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 522 | 0.110 |
Why?
|
| Pain | 3 | 2022 | 398 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 86 | 0.110 |
Why?
|
| Health Education | 1 | 2016 | 191 | 0.110 |
Why?
|
| Viruses | 1 | 2015 | 81 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2015 | 117 | 0.100 |
Why?
|
| Caregivers | 1 | 2016 | 292 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2012 | 755 | 0.090 |
Why?
|
| Viremia | 2 | 2026 | 45 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6811 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 1115 | 0.090 |
Why?
|
| Smoking Prevention | 1 | 2012 | 163 | 0.080 |
Why?
|
| South America | 1 | 2010 | 25 | 0.080 |
Why?
|
| New Zealand | 1 | 2010 | 44 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 23 | 0.080 |
Why?
|
| North America | 1 | 2010 | 113 | 0.080 |
Why?
|
| Physicians | 1 | 2016 | 484 | 0.080 |
Why?
|
| Australia | 1 | 2010 | 128 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 199 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 140 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 152 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 171 | 0.080 |
Why?
|
| Aspirin | 1 | 2010 | 171 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 461 | 0.070 |
Why?
|
| Acute Disease | 1 | 2010 | 665 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 2 | 2019 | 105 | 0.070 |
Why?
|
| Logistic Models | 2 | 2012 | 1268 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 214 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 232 | 0.070 |
Why?
|
| Young Adult | 5 | 2019 | 4773 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 278 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 315 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2012 | 552 | 0.060 |
Why?
|
| Registries | 1 | 2010 | 898 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2010 | 525 | 0.060 |
Why?
|
| Adolescent | 4 | 2020 | 6292 | 0.060 |
Why?
|
| Data Collection | 2 | 2019 | 381 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2679 | 0.060 |
Why?
|
| Virulence | 1 | 2026 | 200 | 0.060 |
Why?
|
| Viral Load | 1 | 2026 | 228 | 0.060 |
Why?
|
| Swine | 1 | 2026 | 395 | 0.060 |
Why?
|
| Virus Replication | 1 | 2026 | 322 | 0.050 |
Why?
|
| Genotype | 1 | 2026 | 670 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2026 | 324 | 0.050 |
Why?
|
| Ghana | 1 | 2023 | 14 | 0.050 |
Why?
|
| Quarantine | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cathartics | 1 | 2023 | 9 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 95 | 0.050 |
Why?
|
| Animals | 5 | 2026 | 21310 | 0.050 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2022 | 22 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2023 | 95 | 0.050 |
Why?
|
| Manometry | 1 | 2022 | 28 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 73 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2018 | 1411 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2024 | 293 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2022 | 175 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 76 | 0.040 |
Why?
|
| Infant | 2 | 2018 | 1682 | 0.040 |
Why?
|
| Fentanyl | 1 | 2022 | 66 | 0.040 |
Why?
|
| Analgesics | 1 | 2022 | 102 | 0.040 |
Why?
|
| Developed Countries | 1 | 2021 | 16 | 0.040 |
Why?
|
| Penicillins | 1 | 2021 | 31 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2022 | 113 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 83 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 160 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 9 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 105 | 0.040 |
Why?
|
| Community Health Workers | 1 | 2020 | 41 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 294 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 419 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 122 | 0.040 |
Why?
|
| United States | 3 | 2018 | 8051 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 100 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 2018 | 20 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2024 | 674 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 54 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2018 | 100 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 489 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 524 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1689 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 371 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2016 | 45 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 847 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 959 | 0.030 |
Why?
|
| Disease Vectors | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 21 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 14 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2015 | 18 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 194 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2019 | 520 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 384 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 458 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 99 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2015 | 61 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 168 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 415 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 803 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 826 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 518 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 543 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 117 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 274 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 427 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 2049 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 94 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 238 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 146 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 392 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2603 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2363 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 860 | 0.020 |
Why?
|